Neuronetics Inc

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neuronetics reports robust Q4 performance, eyes nurse practitioner opportunities

Neuronetics delivered a strong performance in Q4 2022, showcasing revenue growth, operational achievements, and strategic partnerships.
While facing challenges in managing losses and revenue fluctuations, the company is focused on key initiatives and opportunities for future growth.
By leveraging upcoming opportunities with nurse practitioners and addressing analyst inquiries, Neuronetics aims to navigate challenges and drive sustainable growth in 2023.

Neuronetics Inc reports revenue growth and strategic advancements in Q1 2023

Neuronetics Inc's Q1 2023 performance reflects revenue growth, operational advancements, and strategic initiatives aimed at driving market expansion and financial stability.
While facing challenges in gross margin decline and negative EBITDA, the company's focus on cost management, recovery from merger disruption, and revenue guidance raise position it for future success.
With opportunities in expanded patient access, market growth, and product enhancements, Neuronetics is poised to capitalize on its strengths and navigate challenges effectively in the coming quarters.

Neuronetics reports solid Q2 performance, eyes growth amidst challenges

Neuronetics demonstrated resilience and growth in Q2 2023, with revenue increases and strategic advancements in technology and policy.
While facing challenges from closures and relocations, the company remains focused on financial stability and operational efficiency.
Opportunities lie in new technology clearances, favorable policy changes, and the growing demand for TMS therapy education and services.
Overall, Neuronetics' performance, strengths, challenges, and opportunities position the company for continued growth and market impact.

Neuronetics Inc reports solid Q3 earnings, faces challenges in expenses

Neuronetics Inc (STIM) delivered a strong performance in Q3 2023, showcasing revenue growth and operational advancements.
While facing challenges in aligning revenue with operating expenses, the company maintains a solid financial position and pursues growth opportunities.
By focusing on enhancing patient care standards, expanding market reach, and optimizing financial performance, Neuronetics Inc aims to drive sustainable growth and value creation.

Neuronetics Inc posts record revenue in Q4 2023 earnings call

Neuronetics Inc delivered a strong Q4 performance with revenue growth and achieving positive cash flow for the first time. The company's focus on strategic initiatives, regulatory advancements, and revenue guidance for 2024 indicate a positive trajectory for growth and profitability.

Neuronetics Inc reports revenue growth and strategic partnerships in Q1

Neuronetics Inc's Q1 2024 performance reflects revenue growth, operational efficiency improvements, and a strong financial position.
Strengths include successful programs, strategic partnerships, and growth opportunities in new market segments.
Challenges in system sales and revenue collection highlight areas for improvement, while opportunities in market expansion and revenue growth are promising.
Overall, Neuronetics shows resilience, innovation, and a strategic focus on driving growth and improving patient outcomes.

Neuronetics Inc reports Q2 revenue decline, eyes growth opportunities

Neuronetics Inc faced revenue challenges due to a cybersecurity breach but showed resilience in key areas.
Strategic adjustments and positive program results indicate a focus on growth and market expansion.
Acquisition and new debt facility offer opportunities for future expansion and financial stability.

Neuronetics reports solid Q3 earnings, eyes profitability and growth

Neuronetics is focused on optimizing operations, profitability, and cash flow breakeven by Q3 2025.
Greenbrook acquisition approval and strong business position provide a foundation for future growth.
Challenges include managing treatment session weakness and debt levels while pursuing revenue growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS NGS MAC Allows Non-Physician Practitioners with Autonomy to Prescribe TMS

Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners

MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders (“Neuronetics”), and Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH), a leading provider of transcranial magnetic stimulation (“TMS”) therapy (“Greenbrook”), today announced an expanded commercial partnership through year end 2028.

Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership

Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it has settled the litigation filed in the District of Delaware against BrainsWay Ltd. and BrainsWay USA Inc. for unfair competition under the Lanham Act and state law.

Neuronetics Settles Litigation Against BrainsWay

MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced certain preliminary unaudited fourth quarter and full year 2022 revenue results.

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results

New Director Brings Extensive Experience to Poise the Company for Growth New Director Brings Extensive Experience to Poise the Company for Growth

Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

Cardinal Health

Olink Holding AB

Silk Road Medical Inc

Transmedics Group Inc

Despite ongoing macro challenges, medical product stocks like Cardinal Health (CAH), TransMedics Group (TMDX), Olink Holding (OLK), Silk Road Medical (SILK) and Neuronetics (STIM) are likely to gain from strong fundamentals.

5 Winning Medical Product Stocks That Still Have Room to Run

Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?

Does Neuronetics (STIM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Neuronetics (STIM) Is Up 12.75% in One Week: What You Should Know

NeuroStar's technology once again recognized as an effective non-drug treatment for patients NeuroStar's technology once again recognized as an effective non-drug treatment for patients

Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category

The high prevalence of major depressive disorder creates the need for Neuronetics' NeuroStar Advanced Therapy System. Neuronetics is valued below its industry, leaving plenty of room to the upside for the stock.

Neuronetics: Numerous Expansion Opportunities Mean An Outperforming Stock

MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at  ir.neuronetics.com . A replay of the webcast will be archived on the website for approximately 90 days. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com. Investor Contact: Mark KlausnerWestwicke Partners443-213-0501 ir@neuronetics.com Media Contact: EvolveMKD646.517.4220 NeuroStar@evolvemkd.com

Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference

Enhancements further establish the Company's leadership position as the top transcranial magnetic stimulation therapy Enhancements further establish the Company's leadership position as the top transcranial magnetic stimulation therapy

Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations

Neuronetics, Inc. (NASDAQ:STIM ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer Stephen Furlong - Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair Bill Plovanic - Canaccord Marie Thibault - BTIG Operator Good day and thank you for standing by. Welcome to the Neuronetics Report Third Quarter 2022 Financial and Operating Results Conference Call.

Neuronetics, Inc. (STIM) Q3 2022 Earnings Call Transcript

Neuronetics (STIM) delivered earnings and revenue surprises of 36.36% and 11.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates

MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2022.

Neuronetics Reports Third Quarter 2022 Financial and Operating Results

NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health

Neuronetics Announced as Winner by 2022 Merit Awards for Technology

Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS

Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health

MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter 2022 financial and operating results prior to market open on Tuesday, November 8th, 2022. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/h3amkwib. To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com. Investor Contact: Mike Vallie or Mark KlausnerICR Westwicke443-213-0499ir@neuronetics.com Media Contact: EvolveMKD646-517-4220NeuroStar@evolvemkd.com

Neuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call

Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need of treatment Upgrades will enhance and automate the patient candidate experience for all NeuroStar providers, leading to faster patient identification of those in need of treatment

Neuronetics Launches Innovations To NeuroStar® Advanced Therapy's Proprietary TrakStar® Platform

The state-of-the-art training center is the first of its kind to further best practices with transformative NeuroStar Advanced Therapy for Mental Health The state-of-the-art training center is the first of its kind to further best practices with transformative NeuroStar Advanced Therapy for Mental Health

Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony

Latest NeuroStar innovation to simplify the motor threshold determination for clinicians Latest NeuroStar innovation to simplify the motor threshold determination for clinicians

Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy?

Neuronetics Inc (NASDAQ:STIM ) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & CEO Steve Furlong - SVP, CFO & Treasurer Conference Call Participants Adam Maeder - Piper Sandler Margaret Kaczor - William Blair William Plovanic - Canaccord Genuity Marie Thibault - BTIG David Turkaly - JMP Securities Operator Good day, and thank you for standing by. Welcome to the Neuronetics' Reports Second Quarter 2022 Financial and Operating Results Conference Call.

Neuronetics Inc (STIM) CEO Keith Sullivan on Q2 2022 Results - Earnings Call Transcript

Neuronetics (STIM) delivered earnings and revenue surprises of 9.30% and 6.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Neuronetics Inc Stock (STIM)